Empire Genomics, an emerging molecular diagnostics company focused on cancer diagnostics, has recently received approval from the New York State Department of Health for its diagnostic test facility. In addition, its laboratory has received the Clinical Laboratory Improvements Amendments (CLIA) certification from the Centers for Medicaid & Medicare Services.
“This permits our expansion of complete genomic testing services to our clients,” said Anthony Johnson, President and CEO of Empire Genomics. The company is launching a full-service CLIA-certified laboratory for tests and companion diagnostics in oncology, and will start to offer 2 new biomarker tests for myeloma and for prostate cancer in 2014. Empire Genomics; November 12, 2013
